

Dissolution Testing in Quality Control and Drug Development - from USP Vessels to Artificial Intelligence

October 20, 2020, Online Zoom

Program

Tuesday, October 20

- 08.00 Login of participants and lecturers in Zoom
- 09.00 Welcome and information about functions in Zoom
- Session I** **Chair:** Sofia Mattsson, Umeå University & Johan Breitholtz, AstraZeneca
- 09.20 **Introduction**
- 09.30 **The current & future state of QC dissolution testing**
James Mann, AstraZeneca
- 10.05 **The regulatory landscape of dissolution**
Pernilla Örtqvist, Läkemedelsverket
- 10.40 *Pause and slide show about exhibitors*
- 11.15 **Equipment used for dissolution**
Jonas Johansson, AstraZeneca
- 11.50 *Lunch*
- Session II** **Chair:** Jonas Fagerberg, Disruptive materials, Uppsala
- 12.50 **Bio relevant media**
Jennifer Dressmann, Goethe – University
- 13.25 **Linking *in vitro* Dissolution & *in vivo* Drug Product performance**
- Physiologically Based Biopharmaceutics Modelling
Christer Tannergren, AstraZeneca
- 14.00 **Efficacy – immediate (IR) and modified release (MR)**
Susanna Abrahamsén Alami, AstraZeneca

- 14.35 *Pause and the slide show for exhibitors, C. H. A. Berg and wega Informatik AG*
- 14.50 **Dissolution- for intravenously administered formulations**
Nikoletta Fotaki, University of Bath, UK
- 15.25 **Increase bioavailability**
Christel Bergström, Uppsala University
- 16.00 **The dissolution universal strategy tool (DUST)**
Johan Breitholtz, Astra Zeneca
- 16.35 Wrap -up, Sofia Mattsson, Umeå University

The Swedish Academy of Pharmaceutical Sciences gratefully acknowledges contributions from

